These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35445739)

  • 1. Long-term outcomes following drug-eluting balloons vs. thin-strut drug-eluting stents for treatment of recurrent restenosis in drug-eluting stents.
    Wolny R; Kowalik I; Januszek R; Bil J; Figatowski T; Milewski M; Tomasiewicz B; Walczak T; Hrymniak B; Desperak P; Niezgoda P; Chudzik M; Kuźma Ł; Kralisz P; D'Ascenzo F; Hudziak D; Jaguszewski M; Reczuch K; Kubica J; Gil RJ; Dobrzycki S; Bartuś S; Gąsior M; Ochała A; Witkowski A; Wojakowski W; Wańha W
    Kardiol Pol; 2022; 80(7-8):765-773. PubMed ID: 35445739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis.
    Wang G; Zhao Q; Chen Q; Zhang X; Tian L; Zhang X
    Coron Artery Dis; 2019 Nov; 30(7):473-480. PubMed ID: 31464729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials.
    Lee JM; Park J; Kang J; Jeon KH; Jung JH; Lee SE; Han JK; Kim HL; Yang HM; Park KW; Kang HJ; Koo BK; Kim HS
    JACC Cardiovasc Interv; 2015 Mar; 8(3):382-394. PubMed ID: 25703886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.
    Basavarajaiah S; Naganuma T; Latib A; Sticchi A; Ciconte G; Panoulas V; Chieffo A; Montorfano M; Carlino M; Colombo A
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):522-528. PubMed ID: 26715370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
    Moscarella E; Tanaka A; Ielasi A; Cortese B; Coscarelli S; De Angelis MC; Piraino D; Latib A; Grigis G; Bianchi R; Buccheri D; Calabrò P; Tespili M; Silva Orrego P; Colombo A; Varricchio A
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):668-677. PubMed ID: 29356269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.
    Baan J; Claessen BE; Dijk KB; Vendrik J; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; de Winter RJ; Koch KT; Sjauw KD; Beijk MA; Vis MM; Wykrzykowska JJ; Piek JJ; Tijssen JGP; Henriques JPS
    JACC Cardiovasc Interv; 2018 Feb; 11(3):275-283. PubMed ID: 29413242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty.
    Oh PC; Suh SY; Kang WC; Lee K; Han SH; Ahn T; Shin EK
    Korean J Intern Med; 2016 May; 31(3):501-6. PubMed ID: 26951915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Drug-Eluting Stent In-Stent Restenosis With Drug-Eluting Balloons: A Systematic Review and Meta-Analysis.
    Liu S; Worme M; Yanagawa B; Kumar N; Buller CE; Cheema AN; Bagai A
    J Invasive Cardiol; 2018 Oct; 30(10):360-366. PubMed ID: 30108189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Clinical Results Following the Use of Drug-Eluting Balloons for a Bare-Metal Stent and Drug-Eluting Stent Instent Restenosis.
    Lee WC; Fang YN; Fang CY; Chen CJ; Yang CH; Yip HK; Hang CL; Wu CJ; Fang HY
    J Interv Cardiol; 2016 Oct; 29(5):469-479. PubMed ID: 27501848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials.
    Elgendy IY; Mahmoud AN; Elgendy AY; Mojadidi MK; Elbadawi A; Eshtehardi P; Pérez-Vizcayno MJ; Wayangankar SA; Jneid H; David Anderson R; Alfonso F
    Cardiovasc Revasc Med; 2019 Jul; 20(7):612-618. PubMed ID: 30126824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis.
    Rhee TM; Lee JM; Shin ES; Hwang D; Park J; Jeon KH; Kim HL; Yang HM; Han JK; Park KW; Hahn JY; Koo BK; Kim SH; Kim HS
    JACC Cardiovasc Interv; 2018 May; 11(10):969-978. PubMed ID: 29798774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of drug-eluting balloon versus drug-eluting stent treatment of drug-eluting stent in-stent restenosis: A meta-analysis of available evidence.
    Bajraktari G; Jashari H; Ibrahimi P; Alfonso F; Jashari F; Ndrepepa G; Elezi S; Henein MY
    Int J Cardiol; 2016 Sep; 218():126-135. PubMed ID: 27232924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population.
    Marquis-Gravel G; Matteau A; Potter BJ; Gobeil F; Noiseux N; Stevens LM; Mansour S
    Arq Bras Cardiol; 2017 Oct; 109(4):277-283. PubMed ID: 28977052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Coated Balloons Versus Second-Generation Drug-Eluting Stents for the Management of Recurrent Multimetal-Layered In-Stent Restenosis.
    Kawamoto H; Ruparelia N; Latib A; Miyazaki T; Sato K; Mangieri A; Contri R; Stella S; Figini F; Chieffo A; Carlino M; Montorfano M; Colombo A
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1586-94. PubMed ID: 26386758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.